Natera, Inc. (NTRA)
| Market Cap | 57.85B +147.4% |
| Revenue (ttm) | 2.71B +37.8% |
| Net Income | -192.35M |
| EPS | -1.37 |
| Shares Out | 144.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 700,419 |
| Open | 392.90 |
| Previous Close | 390.79 |
| Day's Range | 391.51 - 407.06 |
| 52-Week Range | 167.99 - 437.41 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 383.66 (-4.41%) |
| Est. Earnings | Nov 5, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $383.66, which is a decrease of -4.41% from the latest price.
News
Natera announces MCED assay granted BDD by U.S. FDA
Natera (NTRA) announced that its multi-cancer early detection, MCED, assay has been granted Breakthrough Device designation, BDD, by the U.S. Food and Drug Administration, FDA. The BDD is designed for...
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been grante...
Natera enrolls first patients in new Signatera-guided trial
Natera (NTRA) announced the enrollment of the first patients in a new Signatera-guided trial in melanoma, sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for…
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided tri...
Natera price target raised to $475 from $340 at Barclays
Barclays raised the firm’s price target on Natera (NTRA) to $475 from $340 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Natera announces new data shared at ASTRO 2026 on Signatera
Natera (NTRA) announced new data recently shared at the American Society for Radiation Oncology, ASTRO, 2026 Annual Meeting. The presentations marked Natera’s first participation at ASTRO and a signif...
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Onc...
Natera price target raised to $480 from $365 at Citi
Citi raised the firm’s price target on Natera (NTRA) to $480 from $365 and keeps a Buy rating on the shares after meeting with management. The firm cites Signatera momentum…
AFT, Natera announce launch of AFT-70 NAVIGATE
Alliance Foundation Trials, AFT, and Natera (NTRA) announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease-guided treatment strategy for pat...
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a...
Natera price target raised to $475 from $360 at Guggenheim
Guggenheim raised the firm’s price target on Natera (NTRA) to $475 from $360 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Natera price target raised to $460 from $350 at RBC Capital
RBC Capital raised the firm’s price target on Natera (NTRA) to $460 from $350 and keeps an Outperform rating on the shares. The firm is citing its constructive view of…
Natera announces Signatera receives regulatory approval in Japan
Natera (NTRA) announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. Th...
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japa...
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Confe...
Natera Transcript: 2026 Global Healthcare Conference
Record revenue growth and strong operational leverage were driven by robust adoption of oncology and women's health products, with Signatera and Prospera achieving new milestones. International expansion, product innovation, and AI-driven efficiency support a positive long-term outlook.
Natera Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Q2 saw record growth and strong momentum in MRD adoption, with expanding biopharma partnerships and new product launches. Strategic investments in R&D, AI, and international markets are set to drive long-term growth, with significant opportunities in early cancer detection and rising ASPs.
Natera assumed with a Buy at UBS
UBS assumed coverage of Natera (NTRA) with a Buy rating and $435 price target Nateria is the leader in the large and growing MRD market, with additional support from its…
Natera initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Natera (NTRA) with a Buy rating and $385 price target Natera is the market leader in molecular residual disease testing with its Signatera…
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Natera announces publication of new data in Blood Neoplasia on Signatera
Natera (NTRA) announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory lympho...
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the pro...
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's l...
Natera and Angiex partner in tumor testing using Signatera
Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates, or ND-ADCs. Angiex is conducti...